%0 Journal Article %A Julia Kelly %A Alison Wimms %A Christopher Turnbull %A Alison Mcmillan %A Sonya Craig %A John O'Reilly %A Annabel Nickol %A Emma Hedley %A Meredith Decker %A Leslee Willes %A Peter Calverley %A Adam Benjafield %A John Stradling %A Mary Morrell %T The effect of CPAP on quality of life in patients with ‘very’ mild Obstructive Sleep Apnoea (OSA): Results from a subset of the MERGE Randomised Trial %D 2020 %R 10.1183/13993003.congress-2020.4736 %J European Respiratory Journal %P 4736 %V 56 %N suppl 64 %X Background: The efficacy of CPAP at the mildest end of the OSA spectrum is unclear. The MERGE trial investigated the effect of CPAP on quality of life in patients with mild OSA (Wimms et al. 2019). This subset analysis aimed to determine the effectiveness of CPAP in a subset of patients with ‘very' mild OSA, defined as having mild OSA according to the sensitive AASM 2012 criteria, but no OSA using the earlier AASM 2007 criteria (i.e. AHI >5 to <15 events/hr per AASM 2012, but AHI <5 events/hr per AASM 2007).Methods: The MERGE trial randomised patients with mild OSA (AHI >5 to ≤15 events/hr, AASM 2007 or 2012) in parallel to receive either CPAP plus Standard Care or Standard Care alone for 3 months. A subset of 95 of 301 patients were identified as having ‘very' mild OSA.Results: The subset of 95 ‘very' mild OSA patients had a median (IQR) AHI 6.80(5.7, 8.8) events/hr, and were symptomatic (Vitality 41.9(10.9); ESS 10.3(4.7)). 50 of 95 were allocated to CPAP, and 45 to Standard Care. ‘Very' mild OSA patients had significantly improved Vitality after 3 months of CPAP, compared to Standard Care (+9.2 points, 95% CI +5.6 to +12.7; p<0.0001). Sleepiness also improved (ESS: -3.9, 95% CI -5.3 to -2.5; p<0.0001) as well as fatigue, functionality, anxiety, depression and insomnia. The ‘very' mild OSA patients used their CPAP for a median (IQR) 4:04(2:00, 5:42) hrs:min/night.Conclusions: This subset analysis has shown the clinical effectiveness of CPAP treatment in patients at the mildest end of the disease spectrum, with 'very' mild but symptomatic OSA. The results were similar to those observed in the primary analysis of the MERGE trial.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4736.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). %U